NEW YORK (GenomeWeb News) – BG Medicine today reported second quarter revenues of $1 million, up 62 percent from $622,000 in the second quarter of 2012.

The revenue increase was driven by $972,000 in revenues from sales of the company's BGM Galectin-3 test, a 72 percent jump from the $566,000 it posted in Q2 2012. The remaining $34,000 in revenues came from BG's services business, down 39 percent from $56,000 a year ago.

The company's revenues fell short of the average Wall Street estimate of $1.27 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.

Mar
08
Sponsored by
Swift Biosciences

This webinar will discuss an optimized protocol for methyl-CpG binding domain sequencing (MBD-seq), which enables comprehensive, adequately powered, and cost-effective large-scale methylome-wide association studies (MWAS) of almost all 28 million CpG sites in the genome.

Mar
13
Sponsored by
Agilent

This webinar will share how clinical genetics labs can integrate cytogenetics and molecular data to assess abnormalities using a single sample on a single workflow platform.

Apr
03
Sponsored by
Dovetail Genomics

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research.